CD274 and neoplasm: Immune checkpoint inhibitors (ICIs), especially PD-1/PD-L1 inhibitors, show promise in treating esophageal cancer with notable anti-tumor activity and safety. Cell therapies like Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) enhance T-cell precision in cancer cell recognition and elimination.